Hanall Biopharma

HanAll Biopharma Co. Ltd. is committed to promoting human health and has been providing a portfolio of drugs in the fields of endocrine, circulatory, and urinary system diseases. We focus on discovering and developing innovative drugs for patients with diseases that lack effective treatments. HL161 (INN: batoclimab) is an anti-FcRn antibody drug currently in phase 2 clinical trials for five rare autoimmune diseases worldwide. Another leading candidate drug, HL036 (INN: tanfanercept), is an anti-TNF inhibitor for the treatment of dry eye disease, currently undergoing phase 3 clinical trials in the United States and China.